Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

• मुख्य लेखकों: Debbie Robbrecht (लेखक), Jean‐Jacques Grob (लेखक), Oliver Bechter (लेखक), Matteo Simonelli (लेखक), Bernard Doger (लेखक), Ivan Borbath (लेखक), Marcus O. Butler (लेखक), Tina Cheng (लेखक), Patricia Martin Romano (लेखक), Elvire Pons‐Tostivint (लेखक), Massimo Di Nicola (लेखक), Giuseppe Curigliano (लेखक), Min‐Hee Ryu (लेखक), Alejo Rodriguez‐Vida (लेखक), Dirk Schadendorf (लेखक), Elena Garralda (लेखक), Giovanni Abbadessa (लेखक), Brigitte Demers (लेखक), Amele Amrate (लेखक), Hong Wang (लेखक), Joon Sang Lee (लेखक), Robert Pomponio (लेखक), Rui Wang (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2024-02-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract SAR439459, a 'second‐generation' human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This study reports the pharmacodynamics (PD) and biomarker r...